Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA polymerase subunit gamma-2, mitochondrial (POLG2) is the 55 kDa accessory subunit of the mitochondrial DNA polymerase gamma complex. The holoenzyme comprises one catalytic subunit (POLG) and a dimer of POLG2, forming a heterotrimeric structure. POLG2 enhances the affinity of the POLG catalytic subunit for DNA, increases processivity (enabling long-chain DNA synthesis), and confers salt tolerance to the complex. It fulfills essential functions in mitochondrial DNA replication and maintenance; mutations in POLG2 therefore result in depletion and deletions of mitochondrial genomes, presenting as progressive external ophthalmoplegia and other systemic manifestations. POLG2 directly binds DNA, can oligomerize, and is thought to play structure-specific roles in targeting forked or crossed DNA structures in the mitochondrial nucleoid. Genetic disruption leads to mitochondrial dysfunction and multisystemic disease; no direct drugs presently target POLG2 but its role is central to mitochondrial genetic stability.
No drugs with a characterized mechanism targeting POLG2; inhibition would reduce mitochondrial DNA replication
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA polymerase subunit gamma-2, mitochondrial (POLG2).